Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;29(5):1414-1423.
doi: 10.1007/s43032-021-00678-0. Epub 2021 Jul 6.

Low Molecular Weight Heparins (LMWH) and Implications along Pregnancy: a Focus on the Placenta

Sara Zullino  1 , Sara Clemenza  2 , Federico Mecacci  2 , Felice Petraglia  2
Affiliations
Review

Low Molecular Weight Heparins (LMWH) and Implications along Pregnancy: a Focus on the Placenta

Sara Zullino et al. Reprod Sci. 2022 May.

Abstract

Low molecular weight heparins (LMWH) have been largely studied for their use during pregnancy. The biology and the pharmacology of these molecules are well known and may be summarized in three main mechanisms of action: anti-coagulant, anti-inflammatory, and immunomodulant. The clinical implications of these drugs during pregnancy are mainly related to their action on the placenta, because of the presence of specific molecular and cellular targets, particularly at the trophoblast-endometrial interface. As well as for the prevention and treatment of thromboembolism, LMWH have been largely investigated for the improvement of embryo implantation and for the prevention of placenta-related complications such as preeclampsia, fetal growth restriction, and intrauterine fetal death. However, data on this topic are still unclear. The present review discusses the biological features, the mechanisms of action, and the possible contribution of LMWH to the success of placentation along pregnancy, pointing out the need for future basic science and clinical researches in this important field with the final aim to improve clinical practice in high-risk pregnancies.

Keywords: Immunomodulation; Inflammatory mediators; LMWH; Placenta; Preeclampsia.

PubMed Disclaimer

References

    1. Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. Br. J. Haematol. 2006;133(1):19–34. https://doi.org/10.1111/j.1365-2141.2005.05953.x . - DOI
    1. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S–59S. https://doi.org/10.1378/chest.08-0689 . - DOI
    1. Rosenberg RD. Actions and interactions of antithrombin and heparin. N. Engl. J. Med. 1975;292(3):146–51. https://doi.org/10.1056/NEJM197501162920307 . - DOI
    1. R. D. Rosenberg, R. E. Jordan, L. V Favreau, and L. H. Lam, “Highly active heparin species with multiple binding sites for antithrombin.,” Biochem. Biophys. Res. Commun., vol. 86, no. 4, pp. 1319–1324, 1979, doi: https://doi.org/10.1016/0006-291x(79)90260-2 .
    1. Atha DH, Stephens AW, Rosenberg RD. Evaluation of critical groups required for the binding of heparin to antithrombin. Proc. Natl. Acad. Sci. U. S. A. Feb. 1984;81(4):1030–4. https://doi.org/10.1073/pnas.81.4.1030 . - DOI

Substances

LinkOut - more resources